Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
for Recurrent Non-Muscle Invasive Bladder Carcinoma
56 locations incl. Birmingham
Sponsor: Alliance for Clinical Trials in Oncology
Sex: All·Age: 18+
Code: NCT07000084·Phase 3·Recruiting